



# Sanofi Innovation Awards iAwards

## Sanofi iAwards: Call-for-Proposals

Sanofi, a global biopharmaceutical company is pleased to announce its 5th call for iAward pre-proposals. To date, the iAward program has attracted approximately 900 pre-proposals of which 230 have been invited back as Detailed Proposals. The program has a 10% funding rate and a fourth of all funded iAwards progress to become sponsored research agreements with additional funding.

- Areas of interest: Oncology, Immunology, Rare Diseases & Neurology, and Gene Therapy
- Priority will be given to early stage therapeutics, novel disease targets, mechanisms and screening assays, new disease relevant animal models, biomarkers and technologies that improve drug discovery and development
- Out-of-scope areas: Clinical research, devices, exploratory genomics and target identification approaches

If selected for funding, Sanofi will provide:

- \$125,000 research funding (including institutional indirect costs) for 12 months
- Sanofi scientific expertise, dedicated project management support and a scientific champion
- In-kind resources such as reagents, tool compounds, etc., if deemed necessary to advance the project
- Successful projects could be converted to SRAs and receive additional funding for 2-3 years

### Call for pre-proposals

Sanofi is requesting pre-proposals from academic investigators at participating institutions in multiple therapeutic areas including, immune- oncology, molecular oncology, immunology & inflammation, rare diseases, neurosciences, diabetes and cardiovascular diseases.

A copy of the pre-proposal template is attached and additional information on therapeutic areas of interest is provided below. Only the JSSC and select members of Sanofi and your Institution will have access to your pre-proposal. However, information in the pre-proposal is **NOT** considered confidential and therefore unpublished information should not be disclosed in the pre-proposal. Proposals with third party collaborators other than those from partner institutions within the iAwards Program will not be considered.

- Please limit your completed pre-proposal to two pages, excluding publications.
- Please submit your pre-proposal to:

**The deadline for submission of pre-proposals is July 1, 2019**

Please email Yuxi Lin at [yuxi.lin@ucsf.edu](mailto:yuxi.lin@ucsf.edu) for any questions or concerns

### Sanofi iAwards General Timeline

ACTION	DUE DATE
Notification by Sanofi of pre-proposals chosen to be pursued as Detailed Proposals	12th August
Completion and submission of Detailed Proposals to your Institution	4th October
JSSC meets to review Detailed Proposals	Late November
Institution informed of JSSC funding decisions	Early December



# Sanofi Innovation Awards iAwards

## Areas of Interest

Sanofi is seeking the following type of opportunities in the therapeutic areas provided below:

- Early stage compounds, small molecules or biologics targeting novel disease mechanisms
- Disease relevant targets with validated mechanism of action
- Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
- Novel therapeutic modalities

### ■ MOLECULAR ONCOLOGY

Sanofi priority indications are breast, lung, head and neck, gastro-intestinal, prostate, leukemia, multiple myeloma, pancreas and liver cancers:

- Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
- Small molecule or biologics targeted therapy programs
- Novel Targeted Therapies approaches
- Tumors microenvironment targeting programs

### ■ IMMUNO ONCOLOGY

Mechanisms of innate and acquired resistance to checkpoint blockade

- Immuno-modulatory function of CD38
- Immuno-modulatory function of TGFb
- Immune Cell Engagers
- Systemic oncolytic viruses
- Immuno-conjugates
- Novel ADC targets
- Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
- DC maturation, improved cross-presentation
- Immune profiling methodologies in preclinical and clinical setting
- Novel translational models in IO

### ■ IMMUNOLOGY & INFLAMMATION

- Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
- Rheumatological disorders including Lupus Erythematosus, Rheumatoid Arthritis, psoriatic arthritis and Ankylosing spondylitis
- Autoimmune sequelae of checkpoint inhibition
- Co-stimulation pathways in autoimmune and allergic diseases
- Systems Immunology and single (immune) cell analysis
- Immuno-metabolism

### ■ CARDIOVASCULAR DISEASES

#### Cardiomyopathies

- HCM, DCM and other cardiomyopathies

#### Heart Failure

- HF-preserved ejection fraction (HFpEF) and HF-reduced EF (HFrEF)
- Acute HF

#### Atherosclerotic Vascular Diseases

- Microvascular disease
- Peripheral artery disease
- Coronary artery disease

### ■ DIABETES

- Glucose responsive insulins
- Diabetic Kidney disease
- Beta cell protection &/or regeneration
- Diabetic heart failure & cardiomyocyte fuel utilization
- Novel delivery technologies of large molecule drugs (preferably oral)

### ■ RARE DISEASES

- Gene therapy approaches for rare disorders including neurometabolic, neuromuscular and ophthalmologic diseases
- Research on viral capsids with cell types specificity suitable for local, intrathecal (brain) or systemic delivery
- Novel targets, models and therapeutic concepts for inherited metabolic, nephrologic and bones diseases

### ■ NEUROSCIENCE

- Novel targets / assays for proteinopathies, in particular for tauopathies, but also  $\alpha$ -synuclein, TDP-43
- Remyelination targets and assays, including human IPSC based assays
- Neuroprotection in neurodegenerative diseases including MS, PD, ALS
- Novel targets / models for rare genetic diseases of the central nervous system and peripheral nervous system, including gene therapy approaches
- Microglial biology, in particular in inflammatory milieu
- Blood brain barrier biology, transport mechanisms and neurovascular unit biology
- Biomarkers and imaging methodologies to facilitate disease diagnosis, progression and therapeutic efficacy, or patient stratification, for MS, PD and other neuro- degenerative diseases
- Novel targets to preserve synapse number and function in neurodegenerative diseases, including MS
- Novel targets for CNS insulin resistance, cholesterol homeostasis, and ApoE4 correction
- Neurodegenerative diseases, including MS
- Novel targets for CNS insulin resistance, cholesterol homeostasis, and ApoE4 correction

### ■ RARE BLOOD DISEASES DISORDERS

- Immunogenicity of FVIII and mechanisms of tolerance induction
- Detailed structural understanding of FIXa/FVIIIa/FX complex on phospholipid surfaces
- Better understanding of the relative contribution of FVIII v. VWF deficiency in causing different types of bleeds in various forms of von Willebrand Disease

### ■ GENE THERAPY FOR RARE BLOOD DISORDERS

- Functional validation of potential regulators of fetal hemoglobin expression identified by genome-wide association studies
- Role of different components of the complement cascade in the pathophysiology of rare blood disorders, and potential biomarkers

### ■ BIOLOGICS RESEARCH

- Specific tissue delivery of biologics
- In silico design / Computational biologics
- Intracellular biologics
- Multi-specific protein formats